• No results found

OnabotulinumtoxinA for Hemicrania Continua: open label experience in 9 patients

N/A
N/A
Protected

Academic year: 2020

Share "OnabotulinumtoxinA for Hemicrania Continua: open label experience in 9 patients"

Copied!
7
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1 Demographic details of patients and treatment
Table 2 Headache scores pre- and post- treatment with OnabotulinumtoxinA
Table 3 Headache-associated disability scores pre- and post- treatment with OnabotulinumtoxinA

References

Related documents

Understanding Islamic Finance (Vol. John Wiley & Sons. Behavioral biases of mutual fund investors. Boys will be boys: Gender, overconfidence, and common stock

The product or service being proposed for affinity program status must provide a cost savings or added value to the Chamber’s members that would not otherwise be available to

Although until the mid 1990s plasma derived FvIII was the driving product for plasma fractionators, the demand for recombinant coagulation factors vIII and IX especially in

As teachers’ CS and the students’ attitudes across various proficiency levels toward this phenomenon have been scantly paid attention to systematically in foreign

The mean heart rate of sheep and goats with sinus arrhythmia was significantly lower than those with regular cardiac rhythm ( p <0.001).. The prevalence of the murmurs in sheep

Es wurde der Vorteil von Clopidogrel (sowie von Thie- nopyridinen insgesamt) im Vergleich zu ASS in Bezug auf die Reduktion der Rate aller SVE bei Patienten nach einem